PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12825130-7	2003	A c-Jun/activating protein-1 (AP-1) inhibitor, curcumin, reduced the IL-17-, IL-1beta-, and TNF-alpha-induced MMP-3 mRNA expression, and mitogen-activated protein (MAP) kinase inhibitors (U0126, PD098059, and SB203580) also blocked MMP-3 secretion.	U 0126	188-193	interleukin 1 beta	Homo sapiens	77-85	
12388341-9	2002	Indomethacin, the MEK and p38 inhibitors U-0126 and SB-203580, the protein kinase A inhibitor H-89, and dexamethasone each completely abolished the ability of IL-1beta to induce CRE-driven gene expression but only slightly increased the ability of ISO to induce CRE-driven gene expression in IL-1beta-treated cells.	U 0126	41-47	interleukin 1 beta	Homo sapiens	159-167	
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	interleukin 1 beta	Homo sapiens	82-90	
12444029-6	2002	Human bronchial smooth muscle cells and fibroblasts do not constitutively express ESE-3; however, after stimulation with interleukin-1beta or tumor necrosis factor-alpha, levels of ESE-3 mRNA and protein increase dramatically by 24 h. This cytokine induction is dose-dependent and abrogated by specific inhibitors of the MEK1/2 (U0126) and p38 (SB03580) signal transduction pathways.	U 0126	329-334	interleukin 1 beta	Homo sapiens	121-169	
12464556-10	2002	ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC(50) of 0.34 microM for IL-1beta production and 0.26 microM for TNFalpha synthesis.p38-MAP kinase inhibitor SB 203580 inhibits IL-1beta- and TNF-alpha-synthesis (IC(50)sof 0.052 microM and 0.46 microM) in the same degree as p38-MAP kinase activity (IC(50): 0.34 microM).	U 0126	20-25	interleukin 1 beta	Homo sapiens	185-193	
12177784-8	2002	An inhibitor of extracellular signal-related kinase pathway signalling (U0126) blocked induction of matrix metalloproteinase-1 production induced by keratinocyte-conditioned medium (as well as by epidermal growth factor or interleukin-1beta), and also inhibited proliferation.	U 0126	72-77	interleukin 1 beta	Homo sapiens	223-240	
29457525-9	2018	The expression levels of Bax, caspase-3, and caspase-9 in AFCs decreased significantly in the IL-1beta+U0126 group compared with those in the IL-1beta group.	U 0126	103-108	interleukin 1 beta	Homo sapiens	94-102	
10903976-0	2000	The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.	U 0126	37-42	interleukin 1 beta	Homo sapiens	65-73	
10903976-13	2000	In contrast, UO126 was highly effective at inhibiting IL-1beta-dependent arachidonate release, implicating MEK2 in the activation of the PLA(2) that is involved in IL-1beta-dependent PGE(2) release.	U 0126	13-18	interleukin 1 beta	Homo sapiens	54-62	
10903976-13	2000	In contrast, UO126 was highly effective at inhibiting IL-1beta-dependent arachidonate release, implicating MEK2 in the activation of the PLA(2) that is involved in IL-1beta-dependent PGE(2) release.	U 0126	13-18	interleukin 1 beta	Homo sapiens	164-172	
10845922-5	2000	U0126, a potent inhibitor of the upstream activator of ERK1/2, ie, MEK1/2, suppresses IL-1beta messenger RNA (mRNA) expression in a dose-dependent fashion, showing the implication of this pathway in the transcriptional control of IL-1beta production.	U 0126	0-5	interleukin 1 beta	Homo sapiens	86-94	
10845922-5	2000	U0126, a potent inhibitor of the upstream activator of ERK1/2, ie, MEK1/2, suppresses IL-1beta messenger RNA (mRNA) expression in a dose-dependent fashion, showing the implication of this pathway in the transcriptional control of IL-1beta production.	U 0126	0-5	interleukin 1 beta	Homo sapiens	230-238	
30613914-6	2019	Pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), and AP-1 (tanshinone IIA) attenuated IL-1beta-induced MMP-9 expression.	U 0126	49-54	interleukin 1 beta	Homo sapiens	110-118	
30613914-7	2019	In addition, inhibitors of ERK1/2 (U0126) and JNK (SP600125) attenuated IL-1beta-enhanced AP-1 activity.	U 0126	35-40	interleukin 1 beta	Homo sapiens	72-80	
29709340-12	2018	Pretreatment and co-incubation of pulp cells by 5z-7oxozeaenol (1 and 2.5 muM) and U0126 (10 and 20 muM) prevented the IL-1beta-induced IL-8 and uPA expression.	U 0126	83-88	interleukin 1 beta	Homo sapiens	119-127	
29709340-13	2018	5z-7oxozeaenol and U0126 also attenuated the IL-1beta-induced IL-8 and uPA secretion.	U 0126	19-24	interleukin 1 beta	Homo sapiens	45-53	
28223944-7	2017	ERK1/2 inhibition by the specific MEK1/2 inhibitors PD98059/U0126 significantly attenuated the IL-1beta mediated downregulation of PDZK1, while NF-kappaB, p38 MAPK, and JNK inhibition did not.	U 0126	60-65	interleukin 1 beta	Homo sapiens	95-103	
28295583-9	2017	An ERK1/2-selective inhibitor, U0126, suppressed expression of the IL-1beta gene as well as its protein expression in U937 cells treated with LPS and AMBN.	U 0126	31-36	interleukin 1 beta	Homo sapiens	67-75	
26811545-9	2016	Concordantly, the ERK inhibitor U0126 significantly decreased IL1B-induced IL6, CXCL8, CCL2 and PTGS2 mRNA abundance; IL6, CXCL8, CCL2 and PGF2 alpha release; and NF-kappaB activation.	U 0126	32-37	interleukin 1 beta	Homo sapiens	62-66	
24982891-2	2014	Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone.	U 0126	166-171	interleukin 1 beta	Homo sapiens	201-210	
25239226-6	2015	Induction of IL-6 production by IL-1beta was significantly reduced by addition of p38 MAPK (SB203580), MEK1/2 (U0126) or NF-kappaB (BAY11-7082) inhibitors, with the highest effect being observed with SB203580.	U 0126	111-116	interleukin 1 beta	Homo sapiens	32-40	
24647791-15	2015	LY294002 and U0126 attenuated IL-1beta-induced ICAM-1 expression and sICAM-1 production.	U 0126	13-18	interleukin 1 beta	Homo sapiens	30-38	
26492523-11	2016	Aspirin, U0126, LY294002 and 5z-7-oxozeaenol attenuated the IL-1beta-induced MCP-1 expression.	U 0126	9-14	interleukin 1 beta	Homo sapiens	60-68	
24982891-2	2014	Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone.	U 0126	166-171	interleukin 1 beta	Homo sapiens	277-286	
24073294-11	2013	In vivo, U0126 significantly increased cell apoptosis and decreased cell proliferation in the intestine, increased intestinal permeability, intestinal and lung neutrophil infiltration, and injury, as well as systemic pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta.	U 0126	9-14	interleukin 1 beta	Homo sapiens	265-273	
23567618-7	2013	Mitogen-activated protein/extracellular signal-regulated kinase inhibitor U0126 abrogated TNF-alpha-, IFN-gamma-, and IL-1beta-induced and Janus-activated kinase inhibitor I reduced IFN-gamma-induced IL-33 production.	U 0126	74-79	interleukin 1 beta	Homo sapiens	118-126	
23083134-11	2012	Inhibition of ERK1/2 using U0126 or siRNA abolished EGF and/or IL-1beta-induced cell migration and invasion in a dose-dependent manner.	U 0126	27-32	interleukin 1 beta	Homo sapiens	63-71	
21344389-8	2011	We found that the MEK inhibitor U0126 and the RSK inhibitor BI-D1870 both reduced IL-1B-dependent MMP-1 gene expression in SW1353 cells.	U 0126	32-37	interleukin 1 beta	Homo sapiens	82-87	
22595111-10	2012	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), a mitogen-activated protein kinase kinase (MEK) inhibitor, attenuated IL-1beta-induced sVCAM-1 production.	U 0126	0-5	interleukin 1 beta	Homo sapiens	139-147	
22595111-10	2012	U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), a mitogen-activated protein kinase kinase (MEK) inhibitor, attenuated IL-1beta-induced sVCAM-1 production.	U 0126	7-66	interleukin 1 beta	Homo sapiens	139-147	
21828177-3	2011	IL-1beta increased activin betaA (INHBA) and follistatin (FST) mRNA expression within 6 h. A p38 MAPK inhibitor, SB202190, a MAPK/ERK kinase inhibitor, U0126, and an nuclear factor kappaB pathway inhibitor, SC-514, significantly suppressed the IL-1beta-stimulated INHBA and FST mRNA expression.	U 0126	152-157	interleukin 1 beta	Homo sapiens	0-8	
20100175-6	2010	At 2 h, IL-1beta-induced expression of GM-CSF protein, but not mRNA, was sensitive to the MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] inhibitors PD098059 and U0126.	U 0126	211-216	interleukin 1 beta	Homo sapiens	8-16	
21484156-7	2011	Interestingly, U0126 induced apoptosis and blocked the above-mentioned proteins in a similar way to IL-1beta.	U 0126	15-20	interleukin 1 beta	Homo sapiens	100-108	
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	U 0126	51-56	interleukin 1 beta	Homo sapiens	0-8	
20432452-7	2010	IL-1beta-stimulated ICAM-1 gene expression was attenuated by pretreatment with U0126, SP600125, tanshinone IIA, or helenalin, revealed by ICAM-1 promoter assay and real-time RT-PCR analysis.	U 0126	79-84	interleukin 1 beta	Homo sapiens	0-8	
19616091-6	2009	In addition, the IL-1 beta-induced c-Jun phosphorylation was reduced by pretreatment with U0126 or SP600125.	U 0126	90-95	interleukin 1 beta	Homo sapiens	17-26	
19616091-7	2009	IL-1 beta stimulated the transcriptional activity of wild-type MMP-9 promoter in A549 cells, which was inhibited by U0126, SB203580, SP600125, and helenalin.	U 0126	116-121	interleukin 1 beta	Homo sapiens	0-9	
19616091-9	2009	Finally, the IL-1 beta-induced MMP-9 expression led to cell migration which was attenuated by pretreatment with U0126, SB203580, SP600125, helenalin, or MMP-2/9 inhibitor.	U 0126	112-117	interleukin 1 beta	Homo sapiens	13-22	
15613280-4	2005	These changes are blocked by the MEK1/2 specific inhibitor U0126, indicating that MEK1/2 is essential for IL-1beta signaling in TT cells.	U 0126	59-64	interleukin 1 beta	Homo sapiens	106-114	
19542681-4	2009	An ERK-MAPK pathway inhibitor (U0126), but not a p38 kinase inhibitor (SB203580) or a JNK inhibitor (SP600125), also selectively inhibited IL-1beta-induced MMP-13 production in HAC.	U 0126	31-36	interleukin 1 beta	Homo sapiens	139-147	
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	U 0126	107-112	interleukin 1 beta	Homo sapiens	0-8	
17311279-9	2007	MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	U 0126	121-126	interleukin 1 beta	Homo sapiens	40-48	
15489374-3	2005	IL-1beta induced expression of VCAM-1 protein and mRNA in a time-dependent manner, which was significantly inhibited by inhibitors of MEK1/2 (U0126 and PD-98059), p38 (SB-202190), and c-Jun NH(2)-terminal kinase (JNK; SP-600125).	U 0126	142-147	interleukin 1 beta	Homo sapiens	0-8	
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	U 0126	116-121	interleukin 1 beta	Homo sapiens	14-22	
15389584-5	2005	The IL-1beta induction of ICAM-1 mRNA and protein were partially inhibited by U0126 and PD98059 (specific inhibitors of MEK1/2) and SP600125 [a specific inhibitor of c-Jun-N-terminal kinase (JNK)].	U 0126	78-83	interleukin 1 beta	Homo sapiens	4-12	
15389584-6	2005	U0126 was more potent than other inhibitors to attenuate IL-1beta-induced ICAM-1 expression.	U 0126	0-5	interleukin 1 beta	Homo sapiens	57-65	
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	U 0126	116-121	interleukin 1 beta	Homo sapiens	14-22	
15389584-11	2005	Consistently, IL-1beta stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha which was blocked by helenalin, U0126, or SP600125.	U 0126	143-148	interleukin 1 beta	Homo sapiens	14-22	
12730964-9	2003	SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli.	U 0126	13-18	interleukin 1 beta	Homo sapiens	88-96